Atherosclerosis: a life changing phenomenon

Awani Kumar Rai, Suresh Chandra, Shashi Pratap Singh, Asfa Parveen

Abstract


Atherosclerosis is an inflammatory disease. Because high plasma concentrations of cholesterol, in particular those of low-density lipoprotein (LDL) cholesterol, are one of the principal risk factors for atherosclerosis, the process of atherogenesis has been considered by many to consist largely of the accumulation of lipids within the artery wall; however, it is much more than that.  The lesions of atherosclerosis occur principally in large and medium-sized elastic and muscular arteries and can lead to ischemia of the heart, brain, or extremities, resulting in infarction. They may be present throughout a person’s lifetime. Among patients with established cardiovascular disease, mortality is lower among those who participate in an exercise program than among those who do not. Furthermore, recent studies have reported positive lipid-lowering effects from estrogen and/or progestogen in postmenopausal women but there are still conflicting reports on the use of these agents in dyslipidaemia and in females at risk for CHD. In addition to lowering lipid levels, these antihyperlipidaemic The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many atherosclerotic process.


Keywords


Atherosclerosis, Dyslipidaemia, Antihyperlipidaemic, Cholesterol, Atherogenesis

Full Text:

PDF HTML XML

References


he world health report 2000 – Health systems: improving performance, 2000; WHO, Geneva.

Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost- effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA.1996;276:1172-7.

Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253-8.

Tendera M, Aboyans V, Bartelink ML, Baumgartner I, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2001;32: 2851- 2906.

American Heart Association. Heart Disease and Stroke Statistics: Update. Dallas, TX: American Heart Association, 2005.

Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2008;122(Suppl):S3-S14.

Berenson GS, Pickoff AS. Preventive cardiology and its potential influence on the early natural history of adult heart disease: the Bogalusa Heart Study and the Heart Smart Program. Am J Med Sci. 1995;310(suppl 1):S133-S138.

O’Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.

National Cholesterol Education Program. Third report of the National Cholesterol Education Program Expert Panel on Detection,

Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-421.

Napoli C, D Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest.1997;100:2680–90.

Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M. Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol. 1986;123:109–25.

Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J. 1990;11:3–19

Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Jr., Rosenfeld ME et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb. 1994;14:840–56.

Stary HC. Natural history of calcium deposits in atherosclerosis progression and regression. Z Kardiol. 2000;89:28–35.

Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochimica et Biophysica Acta. 1990;1044:275–83.

Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062–71.

Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Laboratory Investigation. 1996;75:77–85.

Choi JH, Jeong TS, Kim DY, Kim YM, Na HJ, Nam KH, et al. Hematin inhibits atherosclerosis by inhibition of reactive oxygen generation and NF-kB-dependent inflammatory mediators in hyperlipidemic mice. Journal of Cardiovascular Pharmacology. 2003; 42:287–95.

Goff DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment and control in the multi-ethnic study of atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113(5):647-56.

Mitchell BD, Kammerer CM, Blangero J, Mahanev MC, Rainwater DL, Dyke B, et al. Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study. Circulation.1996;94:2159-70.

Syed M, Mark C, John FD. Management of dyslipidemia in adults. The Am Fam Physi. 2000;1:1-12.

Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. New Engl J Med. 1985;312(20):1300-10.

Visavadiya NP, Narasimhacharya AV. Ameliorative effect of Chlorophytum borivilianum root on lipid metabolism in hyperlipidemic rats. Clin Exp Pharmacol Physiol. 2007;34:244-9.

Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol. 1992;43:235-44.

De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-10.

Dormandy J, Heeck L, Vig S. Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin Vasc Surg. 1999;12:118-22.

Espeland MA, O'Leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med. 2005;6:3.

Mitchell JR, Schwartz CJ. Relationship between arterial disease in different sites: a study of the aorta and coronary, carotid, and iliac arteries. Br Med J. 1962;5288:1293-301.

Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002;20:159-69.

Wofford JL, Kahl FR, Howard GR, McKinney WM, Toole JF, Crouse JR. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb. 1991;11:1786-94.

Buchwald H, Varco RL, Matts JP, et al. The POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946–55.

Kuo PT, Kostis JB, Moreyra AE, Hayes JA. Familial type II hyperlipoproteinemia with coronary heart disease: effect of dietcolestipol- nicotinic acid treatment. Chest. 1981;79:286–91.

Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003;92:1287–93.

Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–43.

Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis.

;163:157–64.

Clauss SB, Holmes KW, Hopkins P, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial

hypercholesterolemia. Pediatrics. 2005;116:682–8.

de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106:2231.

McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143:74–80.

Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55:1121–6.

Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2influence on lesion formation. Circ Res. 2002;90:1039–40.

Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Op Lipidol. 1997;8:301–11.

Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876–90

Hansson GK. Vaccination against atherosclerosis: science or fiction? Circulation. 2002;106:1599–601

Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281–91

Katsuda S, Coltrera MD, Ross R, Gown AM. Human atherosclerosis. IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am J Pathol. 1993;142:1787–93.

Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138–46.

Paulsson G, Zhou X, Tornquist E, Hansson GK. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:10–7.

National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda, Md.: National Heart, Lung, and Blood Institute, 1993; (NIH publication no. 93-3095.)

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.

Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-7.

Breslow JL. Cardiovascular disease burden increases, NIH funding decreases. Nat Med. 1997;3:600-1.

Braunwald E. Shattuck Lecture — cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360-9.

Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180:1332-9.

Idem. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295: 369-77.

Ross R. The pathogenesis of atherosclerosis — an update. N Engl J Med. 1986;314:488-500.

Idem. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-9.

Idem. Atherosclerosis: a defense mechanism gone awry. Am J Pathol. 1993;143:987-1002.

Napoli C, D’Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-90.

Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462-78.

Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M. Prelesional events in atherogenesis: accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol. 1986;123:109-25.

Ross R, Glomset JA. Atherosclerosis and the arterial smoothmuscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1996;180:1332–9.

Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction—amarker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168–75.

Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60.

Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med. 2003;115:99S–106S.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–5.

Scotland RS, Morales-Ruiz M, Chen Y, Yu J, Rudic RD, Fulton D, et al. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res. 2002;90:904–10.

Brouet A, Sonveaux P, Dessy C, Balligand JL, Feron O. Hsp90 ensures the transition from the early Ca2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem. 2001;276:32663–9.

Fontana J, FultonD, Chen Y, Fairchild TA, McCabe TJ, FujitaN, et al. Domain mapping studies reveal that theMdomain of hsp90 serves as amolecular scaffold to regulate Akt dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res. 2002;90:866–73.

Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153–7.

Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002;90:40L–80L

Yang ZH, Richard V, von Segesser L, Bauer E, Stulz P, Turina M et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation 1990;82:188–195

Anderson TJ.Assessment and treatment of endothelial dysfunction in coronary artery diseas and implications for therapy. J Am Coll Cardiol. 1999;34:631–8.

Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002;8:1235–42.

Nicholson AC. Expression of CD36 in macrophages and atherosclerosis. The role of lipid regulation and PPARg signalling. Trends Cardiovasc Med. 2004;14:8–12

Tontonoz P, Nagy L, Alvarez JA, Thomazy VA, Evans RM. PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241–52.

Nagy L, Tontonoz P, Alvarez JA, Chen HW, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell. 1998;93:229–40.

Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. Lancet. 1953;265:1053-7.

Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. Lancet. 1953;265:1111-20.

Oldridge N, Gottlieb M, Guyatt G, Jones N, Streiner D, Feeny D. Predictors of health-related quality of life with cardiac rehabilitation after acute myocardial infarction. J Cardiopulm Rehabil. 1998; 18:95-103.

Lemaitre RN, Heckbert SR, Psaty BM, Siscovick DS. Leisure-time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. Arch Intern Med. 1995;155:2302-8.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2018 - Pharmaceutical and Biological Evaluations